Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Detalle, Laurent, Stohr, Thomas, Palomo, Concepción, Piedra, Pedro A., Gilbert, Brian E., Mas, Vicente, Millar, Andrena, Power, Ultan F., Stortelers, Catelijne, Allosery, Koen, Melero, José A., Depla, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2015
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704182/
https://www.ncbi.nlm.nih.gov/pubmed/26438495
http://dx.doi.org/10.1128/AAC.01802-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704182/
https://www.ncbi.nlm.nih.gov/pubmed/26438495
http://dx.doi.org/10.1128/AAC.01802-15

Ejemplares similares